Cochlear in 2026 — Ugly Short Term, But Is the Story Broken?
Down 61% for the year. Guidance slashed nearly in half. It has been a really rough stretch for COH shareholders. But step back and look at what the business actually is — global market leader, technology that nobody else has, and a patient base that keeps growing — and the long term argument doesn't just disappear because of a bad six months.
Cochlear Limited (ASX: COH)
April 22 was the day things got worse. Cochlear came out with a trading update and dropped FY26 underlying net profit guidance to $290–$330 million. That used to be $435–$460 million. A big cut. The stock has lost 61% in 2026 so far and market cap is now down to $6.33 billion. P/E has come back to 18. Management is still saying the long term picture hasn't changed. Whether investors believe that is another question.
Half Year Numbers
Six months to December 2025. Revenue was $1,176 million — up 1% on last year in reported terms, down 2% in constant currency. Unit sales were actually decent, cochlear implants grew 6% to 27,016 units. The problem was the mix. More units went to emerging markets where prices are lower, so revenue didn't keep up with volume. Gross margin fell two points to 73% for the same reason, plus the costs of launching the Nexa System hit at the same time.
Underlying net profit came in at $194.8 million, down 9%. Statutory profit fell harder, down 21% to $161.5 million. Net cash was $173 million so the balance sheet is fine. Dividend held at $2.15 per share, same as last year, 72% payout ratio. Annual yield is sitting at 4.43%.
The Next System
This is really what the next few years hinge on. Twenty years in development. FDA approved. First cochlear implant system anywhere in the world with upgradeable firmware, meaning patients can get software improvements pushed to both the implant and processor without needing new hardware.
The sound processor is the smallest and lightest Cochlear has ever made, all-day battery life, adjusts automatically to different sound environments.
By December it was already 80% of implant sales. Surgeons clearly liked it fast. But rolling it out properly across developed markets meant new registrations, new contracts, new paperwork — and that took longer than anyone expected. First half revenue took the hit. Second half is where management expects it to actually start contributing properly.
Five Things That Killed the FY26 Numbers
First one was volume. Developed markets went soft from January. US was tracking okay until mid-February then fell away through March — hearing aid referrals basically dried up. Europe had its own issues, hospital capacity was tight and industrial action in Italy and Spain made it worse. UK and Germany both built up surgical waiting lists as a result.
Second was the Middle East. Conflict in the region meant order cancellations and delayed deliveries. Cochlear flagged up to $10 million net profit impact from potential receivables provisions there.
Third, lower production volumes meant fixed costs got spread thinner. Gross margin took another one percentage point hit, roughly $20 million in net profit terms.
Fourth, Cochlear decided to pull forward its restructuring program. That brought $18 to $25 million of charges into FY26 that weren't originally planned for this year.
Fifth was the Australian dollar. It went from 66 cents to 71 cents against the USD and from 56 to 61 cents against the euro. Most of Cochlear's revenue is offshore so that kind of move hurts. About $25 million after tax gone just from currency.
Source : ( Company Analysis )
